GANT61 exerts anticancer cell and anticancer stem cell capacity in colorectal cancer by blocking the Wnt/β‑catenin and Notch signalling pathways.

ABSTRACT: The present study aimed to assess the anticancer cell and anticancer stem cell (CSC) effects of GANT61, and its regulatory influence on the Wnt/β‑catenin and Notch signalling pathways in colorectal cancer (CRC). HT‑29 and HCT‑116 cells were treated with 0, 2.5, 5, 10, 20 or 40 µM GANT61, after which relative cell viability and the expression of Gli1, β‑catenin and Notch1, as well as the percentage of CD133⁺ cells, were detected. Subsequently, HT‑29/HCT‑116 cells and CSCs were treated with 20 µM GANT61, 10 mM of the Wnt/β‑catenin pathway agonist HLY78, and 30 mM of the Notch pathway agonist JAG1 (alone or in combination), which was followed by the assessment of cell viability and apoptosis. In both cell lines, GANT61 reduced relative cell viability in a time‑ and dose‑dependent m

SUBMITTER: Si Y 

PROVIDER: S-EPMC9478957 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature